Charles River (CRL) Extends Gene Therapy Offering With New Pact

Charles River Laboratories International, Inc. (CRL) inked an AAV9 production program deal with Navega Therapeutics. The deal will grant Navega Therapeutics access to Charles River’s contract development and manufacturing capabilities and advisory services to produce the AAV gene therapy candidate NT-Z001 for phase 1 clinical trials.The recent move will bolster Charles River’s Biologics Solutions.More on the NewsUsing the accuracy of its AI-enabled zinc finger epigenome regulatory technology, Navega Therape ...